

0866

Ellen L. Gams
Associate General Counsel



August 13, 2002

Amgen Inc.
One Amgen Center Drive
Thousand Oaks, CA 91320-1799
805.447.1000
Direct Dial 805.447.2795
Fax 805.499.8011
Email egams@amgen.com

By Telecopy (202-824-5090 or 202-824-5091)
and by Hand Delivery

Mr. Jonathan G. Katz
Secretary
Securities and Exchange Commission
450 Fifth Street, N.W.
Washington, D.C. 20549

Re: Amgen Inc.; Statements Pursuant to Order No. 4-460

Dear Mr. Katz:

On behalf of Amgen Inc. ("Amgen") enclosed are the following original documents in accordance with the Securities and Exchange Act order dated June 27, 2002 (File No. 4-460) requiring the filing of sworn statements pursuant to Section 21(a)(1) of the Securities Exchange Act of 1934:

1. Statement Under Oath of Principal Executive Officer and Principal Financial Officer Regarding Facts and Circumstances Relating to Exchange Act Filings executed by Kevin W. Sharer, Chairman of the Board, Chief Executive Officer and President of Amgen.
2. Statement under Oath of Principal Executive Officer and Principal Financial Officer Regarding Facts and Circumstances Relating to Exchange Act Filings executed by Richard D. Nanula, Executive Vice President, Finance, Strategy and Communications, and Chief Financial Officer.

Please also acknowledge receipt of the enclosed by file stamping the enclosed (i) copy of this letter and (ii) each copy of the enclosures to this letter and returning the same with the courier.

Please contact the undersigned at (805) 447-2795 if you have any questions or concerns.

Very truly yours,

Ellen L. Gams
Associate General Counsel

RECEIVED
OFFICE OF THE SECRETARY

cc: Kevin W. Sharer
Richard D. Nanula

AUG 13 2002

Enclosures

0866


**STATEMENT UNDER OATH OF PRINCIPAL EXECUTIVE OFFICER
AND PRINCIPAL FINANCIAL OFFICER REGARDING
FACTS AND CIRCUMSTANCES RELATING TO EXCHANGE ACT FILINGS**

I, Richard D. Nanula, state and attest that:

- (1) to the best of my knowledge, based upon a review of the covered reports of Amgen Inc., and, except as corrected or supplemented in a subsequent covered report:
 - no covered report contained an untrue statement of a material fact as of the end of the period covered by such report (or in the case of a report on Form 8-K or definitive proxy materials, as of the date on which it was filed); and
 - no covered report omitted to state a material fact necessary to make the statements in the covered report, in light of the circumstances under which they were made, not misleading as of the end of the period covered by such report (or in the case of a report on Form 8-K or definitive proxy materials, as of the date on which it was filed).
- (2) I have reviewed the contents of this statement with the Company's audit committee.
- (3) In this statement under oath, each of the following, if filed on or before the date of this statement, is a "covered report":
 - Annual Report on Form 10-K for the year ended December 31, 2001, of Amgen Inc.;
 - all reports on Form 10-Q, all reports on Form 8-K and all definitive proxy materials of Amgen Inc. filed with the Commission subsequent to the filing of the Form 10-K identified above; and
 - any amendments to any of the foregoing.



 Richard D. Nanula
 Executive Vice President, Finance,
 Strategy and Communications, and
 Chief Financial Officer
 August 13, 2002

Subscribed and sworn to before me
this 13th day of August 2002.


 Notary Public

My Commission Expires:

September 15, 2005



RECEIVED
OFFICE OF THE SECRETARY

AUG 13 2002